Want to see JP:8095 full AI Analyst Report?
8095 Stock Chart & Stats
¥483.00
-¥7.00(-1.48%)
At close: 4:00 PM EST
¥483.00
-¥7.00(-1.48%)
Day’s Range― - ―
52-Week Range¥456.00 - ¥552.00
Previous CloseN/A
Volume111.30K
Average Volume (3M)89.96K
Market Cap
¥20.78B
Enterprise Value¥31.50K
Total Cash (Recent Filing)¥10.19B
Total Debt (Recent Filing)¥22.65B
Price to Earnings (P/E)9.0
Beta0.65
Next Earnings
Oct 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.5%
Share Statistics
EPS (TTM)54.24
Shares Outstanding41,182,423
10 Day Avg. Volume103,280
30 Day Avg. Volume89,956
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.70
Price to Sales (P/S)0.30
P/FCF Ratio37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginsSustained expansion of gross margin reflects structural improvement in cost base or product mix. Higher gross margins enhance operating leverage, improve resilience to input-cost shocks, and create durable capacity to fund R&D, dividends, or debt reduction over coming quarters.
Consistent Revenue GrowthPositive top-line trend, including a rebound, indicates stable demand and market positioning. Persistent revenue growth supports scale economies, steadier margins, and the ability to invest in pipeline and commercial expansion, making performance less dependent on one-off events.
Return To ProfitabilityRe-establishing positive net income after loss demonstrates operational fixes and improves internal funding capacity. A measurable return to profit supports sustainable cash flows and credibility with lenders and partners, helping strategic execution over the next several quarters.
Bears Say
Earnings VolatilityPronounced swings in net income undermine predictability for capital allocation, dividend coverage, and investment planning. Persistent volatility raises the likelihood that earnings can revert, constraining strategic decisions and increasing the premium required by creditors and partners.
Weak Cash GenerationUnreliable free cash flow and thin conversion of earnings into cash limit the firm’s ability to self-fund capex, R&D, and dividends, and increase reliance on external financing. This structural cash risk reduces flexibility over the medium term and heightens refinancing vulnerability.
Increased Leverage In 2025Higher debt levels in 2025 weaken balance-sheet optionality and raise interest burden. Coupled with earnings and cash volatility, elevated leverage amplifies solvency and refinancing risk, limiting capacity to absorb shocks or pursue growth without additional external funding.
Astena Holdings Co.,Ltd. News
8095 FAQ
What was Astena Holdings Co.,Ltd.’s price range in the past 12 months?
Astena Holdings Co.,Ltd. lowest stock price was ¥456.00 and its highest was ¥552.00 in the past 12 months.
What is Astena Holdings Co.,Ltd.’s market cap?
Astena Holdings Co.,Ltd.’s market cap is ¥20.78B.
When is Astena Holdings Co.,Ltd.’s upcoming earnings report date?
Astena Holdings Co.,Ltd.’s upcoming earnings report date is Oct 13, 2026 which is in 27 days.
How were Astena Holdings Co.,Ltd.’s earnings last quarter?
Astena Holdings Co.,Ltd. released its earnings results on Jul 13, 2026. The company reported ¥20.58 earnings per share for the quarter.
Is Astena Holdings Co.,Ltd. overvalued?
According to Wall Street analysts Astena Holdings Co.,Ltd.’s price is currently Overvalued.
Does Astena Holdings Co.,Ltd. pay dividends?
Astena Holdings Co.,Ltd. pays a Semiannually dividend of ¥9 which represents an annual dividend yield of 3.5%. See more information on Astena Holdings Co.,Ltd. dividends here
What is Astena Holdings Co.,Ltd.’s EPS estimate?
Astena Holdings Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astena Holdings Co.,Ltd. have?
Astena Holdings Co.,Ltd. has 41,182,423 shares outstanding.
What happened to Astena Holdings Co.,Ltd.’s price movement after its last earnings report?
Astena Holdings Co.,Ltd. reported an EPS of ¥20.58 in its last earnings report. Following the earnings report the stock price went up 0.762%.
Which hedge fund is a major shareholder of Astena Holdings Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:8095
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astena Holdings Co.,Ltd.
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling active pharmaceutical ingredients (APIs) and vital medical supplies used in treatments for fever reduction, pain relief, inflammation management, and blood vessel constriction. The Medical division focuses on biotechnology-related activities, providing support services for drug development and distributing essential medical equipment. The Health & Beauty Care, and Food segment is responsible for marketing non-prescription medications, raw materials for food and functional food products, and cosmetic ingredients. This division also manages direct-to-consumer sales through online and mail-order platforms, alongside offering contract manufacturing services for cosmetic items. Additionally, Astena Holdings' Industrial Chemicals division produces and supplies specialized chemicals for surface treatment and other industrial applications, serving sectors such as printed circuit boards, electronic devices, general plating processes, and semiconductors. The company, initially known as Iwaki & Co., Ltd., officially adopted the name Astena Holdings Co., Ltd. in June 2021.
Technical Analysis
Pharmarise Holdings Corp.
―
Ohki Health Care Holdings, Inc.
―
Medical System Network Co., Ltd.
―
Tsubota Laboratory Incorporated
―
Chordia Therapeutics Inc.
―